Metformin‐Associated Lactic Acidosis During Docetaxel Therapy for Castration‐Resistant Prostate Cancer: A Case Report

ABSTRACT Introduction Docetaxel is a key treatment for castration‐resistant prostate cancer and is administered with prednisolone, which increases the risk of steroid‐induced diabetes. Its myelosuppressive effect also increases vulnerability to febrile neutropenia. Metformin is widely used for glyce...

Full description

Saved in:
Bibliographic Details
Main Authors: Y. Inoue, A. Niimi, T. Kudo, U. Yoshizaki, Y. Sato, H. Kume
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:IJU Case Reports
Subjects:
Online Access:https://doi.org/10.1002/iju5.70055
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850109245735829504
author Y. Inoue
A. Niimi
T. Kudo
U. Yoshizaki
Y. Sato
H. Kume
author_facet Y. Inoue
A. Niimi
T. Kudo
U. Yoshizaki
Y. Sato
H. Kume
author_sort Y. Inoue
collection DOAJ
description ABSTRACT Introduction Docetaxel is a key treatment for castration‐resistant prostate cancer and is administered with prednisolone, which increases the risk of steroid‐induced diabetes. Its myelosuppressive effect also increases vulnerability to febrile neutropenia. Metformin is widely used for glycemic control; however, elderly cancer patients are particularly susceptible to metformin‐associated lactic acidosis, necessitating careful management of sick‐day and febrile neutropenia during chemotherapy. Case Presentation We report a 70‐year‐old male with castration‐resistant prostate cancer and diabetes mellitus who developed febrile neutropenia on Day 5 following docetaxel initiation. He progressed to shock with severe metabolic acidosis on Day 7 and died despite intensive care, including continuous renal replacement therapy. A retrospective review revealed continued metformin use despite prodromal fatigue and loss of appetite, likely due to impaired judgment. Conclusion This case may have involved septic shock, but metformin likely worsened the lactic acidosis. It highlights the need for sick‐day education and monitoring in elderly cancer patients.
format Article
id doaj-art-9164818e64624b248bd56ecdd652cd39
institution OA Journals
issn 2577-171X
language English
publishDate 2025-07-01
publisher Wiley
record_format Article
series IJU Case Reports
spelling doaj-art-9164818e64624b248bd56ecdd652cd392025-08-20T02:38:09ZengWileyIJU Case Reports2577-171X2025-07-018441141410.1002/iju5.70055Metformin‐Associated Lactic Acidosis During Docetaxel Therapy for Castration‐Resistant Prostate Cancer: A Case ReportY. Inoue0A. Niimi1T. Kudo2U. Yoshizaki3Y. Sato4H. Kume5Department of Urology The New Tokyo Hospital Chiba JapanDepartment of Urology The New Tokyo Hospital Chiba JapanDepartment of Urology National Center for Global Health and Medicine Tokyo JapanDepartment of Urology The New Tokyo Hospital Chiba JapanDepartment of Urology The New Tokyo Hospital Chiba JapanDepartment of Urology, Graduate School of Medicine The University of Tokyo Tokyo JapanABSTRACT Introduction Docetaxel is a key treatment for castration‐resistant prostate cancer and is administered with prednisolone, which increases the risk of steroid‐induced diabetes. Its myelosuppressive effect also increases vulnerability to febrile neutropenia. Metformin is widely used for glycemic control; however, elderly cancer patients are particularly susceptible to metformin‐associated lactic acidosis, necessitating careful management of sick‐day and febrile neutropenia during chemotherapy. Case Presentation We report a 70‐year‐old male with castration‐resistant prostate cancer and diabetes mellitus who developed febrile neutropenia on Day 5 following docetaxel initiation. He progressed to shock with severe metabolic acidosis on Day 7 and died despite intensive care, including continuous renal replacement therapy. A retrospective review revealed continued metformin use despite prodromal fatigue and loss of appetite, likely due to impaired judgment. Conclusion This case may have involved septic shock, but metformin likely worsened the lactic acidosis. It highlights the need for sick‐day education and monitoring in elderly cancer patients.https://doi.org/10.1002/iju5.70055castration‐resistant prostate cancerchemotherapymetformin‐associated lactic acidosispatient educationsick‐day management
spellingShingle Y. Inoue
A. Niimi
T. Kudo
U. Yoshizaki
Y. Sato
H. Kume
Metformin‐Associated Lactic Acidosis During Docetaxel Therapy for Castration‐Resistant Prostate Cancer: A Case Report
IJU Case Reports
castration‐resistant prostate cancer
chemotherapy
metformin‐associated lactic acidosis
patient education
sick‐day management
title Metformin‐Associated Lactic Acidosis During Docetaxel Therapy for Castration‐Resistant Prostate Cancer: A Case Report
title_full Metformin‐Associated Lactic Acidosis During Docetaxel Therapy for Castration‐Resistant Prostate Cancer: A Case Report
title_fullStr Metformin‐Associated Lactic Acidosis During Docetaxel Therapy for Castration‐Resistant Prostate Cancer: A Case Report
title_full_unstemmed Metformin‐Associated Lactic Acidosis During Docetaxel Therapy for Castration‐Resistant Prostate Cancer: A Case Report
title_short Metformin‐Associated Lactic Acidosis During Docetaxel Therapy for Castration‐Resistant Prostate Cancer: A Case Report
title_sort metformin associated lactic acidosis during docetaxel therapy for castration resistant prostate cancer a case report
topic castration‐resistant prostate cancer
chemotherapy
metformin‐associated lactic acidosis
patient education
sick‐day management
url https://doi.org/10.1002/iju5.70055
work_keys_str_mv AT yinoue metforminassociatedlacticacidosisduringdocetaxeltherapyforcastrationresistantprostatecanceracasereport
AT aniimi metforminassociatedlacticacidosisduringdocetaxeltherapyforcastrationresistantprostatecanceracasereport
AT tkudo metforminassociatedlacticacidosisduringdocetaxeltherapyforcastrationresistantprostatecanceracasereport
AT uyoshizaki metforminassociatedlacticacidosisduringdocetaxeltherapyforcastrationresistantprostatecanceracasereport
AT ysato metforminassociatedlacticacidosisduringdocetaxeltherapyforcastrationresistantprostatecanceracasereport
AT hkume metforminassociatedlacticacidosisduringdocetaxeltherapyforcastrationresistantprostatecanceracasereport